Pricing Log in Create free account

Denali Therapeutics Inc. (DNLI) vs Tarsus Pharmaceuticals, Inc. (TARS)

Denali Therapeutics Inc. and Tarsus Pharmaceuticals, Inc. are both Biotechnology companies. Denali Therapeutics Inc. and Tarsus Pharmaceuticals, Inc. are of similar size ($3.3B and $3.2B). Tarsus Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 86.3% against −93.4%. Tarsus Pharmaceuticals, Inc. has the higher net margin (−102.9% vs −1,388.2%) and the higher return on invested capital (0.00% vs −80.0%). Across the 17 metrics below, Tarsus Pharmaceuticals, Inc. leads on 9 and Denali Therapeutics Inc. on 8.

Valuation

Metric DNLI TARS Biotechnology median
P/E n/m n/m 10.26
P/S 165.44 4.59 9.18
P/B 4.04 30.12 2.05
Price to free cash flow n/m 133.67 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 142.89 4.25 8.98
Earnings yield (8.69%) (22.50%) (34.89%)
Free cash flow yield (12.01%) 0.75% (24.52%)

Profitability

Metric DNLI TARS Biotechnology median
Gross margin 98.74% 93.21% 65.16%
Operating margin (2,348.95%) (102.04%) 0.00%
Net margin (1,388.24%) (102.93%) 0.00%
Free cash flow margin (1,986.81%) 4.76% 0.00%
Return on equity (33.94%) (319.84%) (50.12%)
Return on assets (27.20%) (135.04%) (45.60%)
Return on invested capital (80.00%) 0.00% 0.00%

Growth

Metric DNLI TARS Biotechnology median
Revenue growth (TTM) (93.40%) 86.34% 6.26%
EPS growth (last fiscal year) (15.56%) 48.21% 29.88%
Revenue growth, 5-year CAGR 20.67% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DNLI TARS Biotechnology median
Debt to equity 0.01 0.70 0.00
Current ratio 6.21 1.96 4.89
Net debt to EBITDA 1.56 4.66 1.01

Dividend

Metric DNLI TARS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DNLI TARS Biotechnology median
Market cap 3.16b 3.33b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack